Evrys Bio Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $4.71M

  • Investors
  • 10

Evrys Bio General Information

Description

Developer of antiviral drugs intended to enhance the natural ability of sirtuins to combat infections. The company's drugs improve the ability of the infected host cell to defend against pathogen infection, enabling doctors with broad-spectrum treatments that harness the body's natural immune mechanisms.

Contact Information

Website
www.evrysbio.com
Formerly Known As
Forge Life Science
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3805 Old Easton Road
  • Doylestown, PA 18902
  • United States
+1 (215) 000-0000
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 3805 Old Easton Road
  • Doylestown, PA 18902
  • United States
+1 (215) 000-0000

Evrys Bio Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evrys Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
18. Later Stage VC (Series B) 06-Sep-2022 $4.71M 000.00 Completed Product Development
17. Later Stage VC 01-Dec-2022 00000 00.00 Completed Product Development
16. Grant 20-Aug-2021 00000 00.00 Completed Product Development
15. Grant 15-Aug-2021 00.00 00.00 Completed Startup
14. Grant 13-Jul-2021 000.00 00.00 Completed Startup
13. Later Stage VC (Series A2) 01-Jan-2021 00.00 00.00 Completed Startup
12. Grant 31-Aug-2020 00000 00.000 Completed Startup
11. Grant 24-Jun-2020 00000 00.000 Completed Startup
10. Later Stage VC 20-May-2020 $1.2M $7.88M Completed Startup
9. Grant 31-Jul-2019 $3M $6.67M Completed Startup
To view Evrys Bio’s complete valuation and funding history, request access »

Evrys Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antiviral drugs intended to enhance the natural ability of sirtuins to combat infections. The company's dru
Drug Discovery
Doylestown, PA
16 As of 2023
000.00
00000000000 000.00

00000

erit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur s
0000 000000000
San Diego, CA
00 As of 0000
00000
00000 0000-00-00
00000000000 00000

000

lit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidat
0000 000000000
San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evrys Bio Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ansun Biopharma Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
Vir Formerly VC-backed San Francisco, CA 000 00000 00000000 00000
Assembly Biosciences Formerly VC-backed San Francisco, CA 00 000.00 00000000 000.00
Aligos Therapeutics Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
Enanta Pharmaceuticals Formerly VC-backed Watertown, MA 000 00000 00000000000 00000
You’re viewing 5 of 11 competitors. Get the full list »

Evrys Bio Patents

  • 36

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 27

    Granted

  • 8

    Pending

  • 000

    Expiring in next 12 mo

Evrys Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4271675-A1 Anti-tumor compositions and methods Pending 31-Dec-2020 000000000
US-20240109883-A1 Anti-tumor compositions and methods Pending 31-Dec-2020 0000000000
US-20210139475-A1 Broad spectrum antiviral compositions and methods Active 18-Oct-2017 00000000000
EP-3697783-A4 Broad spectrum antiviral compositions and methods Pending 18-Oct-2017 00000000000
EP-3697783-A1 Broad spectrum antiviral compositions and methods Pending 18-Oct-2017 C07D491/056
To view Evrys Bio’s complete patent history, request access »

Evrys Bio Executive Team (12)

Name Title Board Seat
Lillian Chiang Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Karen Monzon Controller
Dana Fowlkes Ph.D Chief Business Officer & Head of Business Development
Ileana Cristea Ph.D Co-Founder & Member of Scientific Advisory Board
Jens Knudsen Chief Financial Officer
You’re viewing 5 of 12 executive team members. Get the full list »

Evrys Bio Board Members (7)

Name Representing Role Since
Brian Pusch Self Business Advisor & Board Member 000 0000
Lillian Chiang Ph.D Evrys Bio Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Richard Whitley MD Self Board Member & Clinical Advisor 000 0000
Robert Drakas Ph.D ShangPharma Innovation Board Observer 000 0000
Steven Holtzman Self Member of Business Advisory Board & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Evrys Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evrys Bio Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ben Franklin Technology Partners of Northeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
Ben Franklin Technology Partners of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
CARES Act Government Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Evrys Bio FAQs

  • When was Evrys Bio founded?

    Evrys Bio was founded in 2012.

  • Who is the founder of Evrys Bio?

    Lillian Chiang Ph.D, Emre Koyuncu Ph.D, Ileana Cristea Ph.D, and Thomas Shenk Ph.D are the founders of Evrys Bio.

  • Who is the CEO of Evrys Bio?

    Lillian Chiang Ph.D is the CEO of Evrys Bio.

  • Where is Evrys Bio headquartered?

    Evrys Bio is headquartered in Doylestown, PA.

  • What is the size of Evrys Bio?

    Evrys Bio has 16 total employees.

  • What industry is Evrys Bio in?

    Evrys Bio’s primary industry is Drug Discovery.

  • Is Evrys Bio a private or public company?

    Evrys Bio is a Private company.

  • What is Evrys Bio’s current revenue?

    The current revenue for Evrys Bio is 00000.

  • How much funding has Evrys Bio raised over time?

    Evrys Bio has raised $14.3M.

  • Who are Evrys Bio’s investors?

    Ben Franklin Technology Partners of Northeastern Pennsylvania, Ben Franklin Technology Partners of Southeastern Pennsylvania, National Institutes of Health, United States Department of Defense, and CARES Act are 5 of 10 investors who have invested in Evrys Bio.

  • Who are Evrys Bio’s competitors?

    Ansun Biopharma, Vir, Assembly Biosciences, Aligos Therapeutics, and Enanta Pharmaceuticals are some of the 11 competitors of Evrys Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »